































33. Li T-T, Zhang H, Huang S-Y, Pei X, Lin Q, Tian S, et al. Preparation and property evaluations of PCL/PLA composite films. *J Polym Res* 2021;28(5):1-9. doi: 10.1007/s10965-021-02439-8
34. Tort S, Han D, Steckl AJ. Self-inflating floating nanofiber membranes for controlled drug delivery. *Int J Pharm* 2020;579:119164. doi: 10.1016/j.ijpharm.2020.119164
35. Kamble R, Mehtre R, Mehta P, Nangare P, Patil S. Albendazole electrospun nanofiber films: in-vitro and ex-vivo assessment. *BioNanoSci* 2019;9(3):625-36. doi: 10.1007/s12668-019-00627-x
36. Ravikumar R, Ganesh M, Senthil V, Ramesh YV, Jakki SL, Choi EY. Tetrahydro curcumin loaded PCL-PEG electrospun transdermal nanofiber patch: Preparation, characterization, and in vitro diffusion evaluations. *J Drug Deliv Sci Technol* 2018;44:342-8. doi: 10.1016/j.jddst.2018.01.016
37. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. *AAPS J* 2005;7(4):E320-33. doi: 10.1208/aapsj070479
38. Mishra D, Gilhotra R. Design and characterization of bioadhesive in situ gelling ocular inserts of gatifloxacin sesquihydrate. *DARU J Pharm Sci* 2008;16(1):1-8.
39. De Souza JF, Maia KN, Patrício PSDO, Fernandes-Cunha GM, Da Silva MG, Jensen CEDM, et al. Ocular inserts based on chitosan and brimonidine tartrate: Development, characterization and biocompatibility. *J Drug Deliv Sci Technol* 2016;32:21-30. doi: 10.1016/j.jddst.2016.01.008
40. Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. *AAPS PharmSciTech* 2011;12(4):1335-47. doi: 10.1208/s12249-011-9780-3
41. Mealy JE, Fedorchak MV, Little SJ. In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate. *Acta Biomater* 2014;10(1):87-93. doi: 10.1016/j.actbio.2013.09.024
42. Khazaei A, Saednia S, Saiee J, Kazem-Rostami M, Sadeghpour M, Borazjani MK, et al. Grafting amino drugs to poly (acrylate-alt-maleic anhydride) as a potential method for drug release. *J Braz Chem Soc* 2013;34:1109-15. doi: 10.5935/0103-5053.20130145
43. Fosca M, Rau JV, Uskoković V. Factors influencing the drug release from calcium phosphate cements. *Bioact Mater* 2022;7:341-63. doi: 10.1016/j.bioactmat.2021.05.032
44. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. *Drugs Aging* 1998;15(3):225-41. doi: 10.2165/00002512-199812030-00005
45. Suzuki G, Kunkane E, Shinno K, Kozai S, Kurata M, Kawamura A. Ocular and systemic pharmacokinetics of brimonidine and timolol after topical administration in rabbits: comparison between fixed-combination and single drugs. *Ophthalmol Ther* 2020;9(1):115-25. doi: 10.1007/s40123-020-00229-x
46. Rodrigo MJ, Cardiel MJ, Fraile JM, Mendez-Martinez S, Martínez-Rincón T, Subias M, et al. Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model. *Biomater Sci* 2020;8(22):6246-60. doi: 10.1039/d0bm01013h
47. Zhao Y, Huang C, Zhang Z, Hong J, Xu J, Sun X, et al. Sustained release of brimonidine from BRI/SR/TPU implant for treatment of glaucoma. *Drug Deliv* 2022;29(1):613-23. doi: 10.1080/10717544.2022.2039806